Sevelda P - Search Results

1

Lunar phases and survival of breast cancer patients--a statistical analysis of 3,757 cases.

Peters-Engl C, Frank W, Kerschbaum F, Denison U, Medl M, Sevelda P. Peters-Engl C, et al. Among authors: sevelda p. Breast Cancer Res Treat. 2001 Nov;70(2):131-5. doi: 10.1023/a:1012907308443. Breast Cancer Res Treat. 2001. PMID: 11768603

2

Color-coded and spectral Doppler flow in breast carcinomas--relationship with the tumor microvasculature.

Peters-Engl C, Medl M, Mirau M, Wanner C, Bilgi S, Sevelda P, Obermair A. Peters-Engl C, et al. Among authors: sevelda p. Breast Cancer Res Treat. 1998 Jan;47(1):83-9. doi: 10.1023/a:1005992916193. Breast Cancer Res Treat. 1998. PMID: 9493979

3

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M. Peters-Engl C, et al. Among authors: sevelda p. Br J Cancer. 1999 Oct;81(4):662-6. doi: 10.1038/sj.bjc.6690744. Br J Cancer. 1999. PMID: 10574252 Free PMC article.

4

Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study.

Peters-Engl C, Medl M, Denison U, Sevelda P, Leodolter S, Petru E. Peters-Engl C, et al. Among authors: sevelda p. Anticancer Res. 2001 Sep-Oct;21(5):3701-6. Anticancer Res. 2001. PMID: 11848547 Clinical Trial.

5

Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.

Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Nagele F, et al. Among authors: sevelda p. Obstet Gynecol. 1995 Aug;86(2):259-64. doi: 10.1016/0029-7844(95)00126-c. Obstet Gynecol. 1995. PMID: 7617357

6

The application of fibrin glue after axillary lymphadenectomy in the surgical treatment of human breast cancer.

Medl M, Mayerhofer K, Peters-Engl C, Mahrhofer P, Huber S, Buxbaum P, Sevelda P, Leodolter S. Medl M, et al. Among authors: sevelda p. Anticancer Res. 1995 Nov-Dec;15(6B):2843-5. Anticancer Res. 1995. PMID: 8669876 Clinical Trial.

7

Prognostic factors related to recurrent endometrial carcinoma following initial surgery.

Vavra N, Denison U, Kucera H, Barrada M, Kurz C, Salzer H, Sevelda P. Vavra N, et al. Among authors: sevelda p. Acta Obstet Gynecol Scand. 1993 Apr;72(3):205-9. doi: 10.3109/00016349309013373. Acta Obstet Gynecol Scand. 1993. PMID: 8385857

8

DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer.

Medl M, Sevelda P, Czerwenka K, Dobianer K, Hanak H, Hruza C, Klein M, Leodolter S, Müllauer-Ertl S, Rosen A, et al. Medl M, et al. Among authors: sevelda p. Gynecol Oncol. 1995 Dec;59(3):321-6. doi: 10.1006/gyno.1995.9969. Gynecol Oncol. 1995. PMID: 8522248

9

TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.

Peters-Engl C, Buxbaum P, Ogris E, Sevelda P, Medl M. Peters-Engl C, et al. Among authors: sevelda p. Anticancer Res. 1998 Nov-Dec;18(6B):4635-9. Anticancer Res. 1998. PMID: 9891532

10

Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer.

Obermair A, Petru E, Windbichler G, Peters-Engl C, Graf AH, Stummvoll W, Kaider A, Kurschel S, Kölbl H, Sevelda P. Obermair A, et al. Among authors: sevelda p. Oncol Rep. 2000 May-Jun;7(3):639-44. doi: 10.3892/or.7.3.639. Oncol Rep. 2000. PMID: 10767382

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters